Key Takeaways
- • Altaris Capital Partners is acquiring Simulations Plus in an all-cash take-private transaction valued at $375 million, with stockholders receiving $18.50 per share in cash.
- • The deal represents a consolidation move in the health tech sector, with Altaris acquiring a specialized software and modeling firm focused on pharmaceutical and life sciences applications.
- • Simulations Plus stockholders will exit their positions at the fixed per-share price, eliminating public market exposure for equity holders.
- • The transaction is structured as a take-private, meaning Simulations Plus will be delisted from public markets following deal completion.
Summary
Altaris Capital Partners has agreed to acquire Simulations Plus in an all-cash take-private transaction valued at $375 million, according to the transaction announcement. Under the terms of the acquisition agreement, Simulations Plus stockholders will receive $18.50 per share in cash consideration.
The deal represents Altaris's strategic investment in the health technology sector, acquiring a company with specialized capabilities in pharmaceutical modeling and simulation software. Simulations Plus has built a focused business around tools and technologies used in drug development and life sciences research, serving pharmaceutical companies and contract research organizations.
The transaction structure as a take-private will result in Simulations Plus being delisted from public markets. Shareholders holding positions in the company will have their equity positions liquidated at the announced per-share price of $18.50, providing a defined exit opportunity at a fixed valuation.
The acquisition reflects continued consolidation activity within the health tech and life sciences software sectors, where larger capital sources have increasingly pursued acquisitions of specialized technology and modeling firms to build integrated platforms and expand service offerings to pharmaceutical clients.
The deal represents Altaris's strategic investment in the health technology sector, acquiring a company with specialized capabilities in pharmaceutical modeling and simulation software. Simulations Plus has built a focused business around tools and technologies used in drug development and life sciences research, serving pharmaceutical companies and contract research organizations.
The transaction structure as a take-private will result in Simulations Plus being delisted from public markets. Shareholders holding positions in the company will have their equity positions liquidated at the announced per-share price of $18.50, providing a defined exit opportunity at a fixed valuation.
The acquisition reflects continued consolidation activity within the health tech and life sciences software sectors, where larger capital sources have increasingly pursued acquisitions of specialized technology and modeling firms to build integrated platforms and expand service offerings to pharmaceutical clients.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.